CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript